XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

SUPPLEMENTAL FINANCIAL INFORMATION | 6 Months Ended
--- | ---
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
SUPPLEMENTAL FINANCIAL INFORMATION | SUPPLEMENTAL FINANCIAL INFORMATION Allowance for Doubtful Accounts The following table is a summary of the changes in our allowance for doubtful accounts for the three and six months ended June 30, 2024 and 2023.
| Three Months Ended June 30, | Six Months Ended June 30,
(in millions) | 2024 | 2023 | 2024 | 2023
Balance at beginning of period | $ | 121 |  | $ | 122 |  | $ | 129 |  | $ | 114 |
Charged to costs and expenses | 3 |  | 9 |  | 2 |  | 16 |
Write-offs | (1) |  | (5) |  | (7) |  | (6) |
Currency translation adjustments | — |  | 2 |  | (1) |  | 4 |
Balance at end of period | $ | 123 |  | $ | 128 |  | $ | 123 |  | $ | 128 |
Inventories
(in millions) | June 30, 2024 | December 31, 2023
Raw materials | $ | 750 |  | $ | 731 |
Work in process | 308 |  | 285 |
Finished goods | 1,927 |  | 1,808 |
Inventories | $ | 2,985 |  | $ | 2,824 |
Property, Plant and Equipment, Net
(in millions) | June 30, 2024 | December 31, 2023
Property, plant and equipment, at cost | $ | 10,774 |  | $ | 11,223 |
Accumulated depreciation | (6,460) |  | (6,790) |
Property, plant and equipment, net | $ | 4,314 |  | $ | 4,433 |
Impairment of Manufacturing Facility Our manufacturing facility in Opelika, Alabama was one of three Baxter manufacturing facilities that produced dialyzers used in hemodialysis (HD) treatments. The competitive environment has increased the global supply of those products and, in connection with our initiatives to streamline our manufacturing footprint and improve our profitability, we made the decision in the second quarter of 2023 to cease production of dialyzers at the Opelika facility near the end of 2023. As a result of our decision to cease dialyzer production at this manufacturing facility, we performed a trigger-based recoverability assessment of its long-lived assets, which consist of a building and manufacturing equipment, including specialized equipment used in the production of dialyzers. The carrying amount of that asset group exceeded the estimated undiscounted cash flows expected to be generated, and we recognized an impairment charge of $243 million, classified within cost of sales in the accompanying condensed consolidated statements of loss, during the second quarter of 2023 to reduce the carrying amounts to their estimated fair values. The fair values of the building and manufacturing equipment tested for impairment during the second quarter of 2023 were determined based on transaction prices of comparable assets. Significant assumptions used in the determination of the fair values included the identification of representative comparable assets. Our long-lived asset fair value measurements are classified as Level 3 in the fair value hierarchy because they involve significant unobservable inputs. Interest Expense, Net
| Three Months Ended June 30, |  | Six Months Ended June 30,
(in millions) | 2024 | 2023 |  | 2024 | 2023
Interest expense, net of capitalized interest | $ | 104 |  | $ | 132 |  |  | $ | 207 |  | $ | 259 |
Interest income | (19) |  | (8) |  |  | (44) |  | (18) |
Interest expense, net | $ | 85 |  | $ | 124 |  |  | $ | 163 |  | $ | 241 |
Other (Income) Expense, Net
| Three Months Ended June 30, |  | Six Months Ended June 30,
(in millions) | 2024 | 2023 |  | 2024 | 2023
Foreign exchange losses, net | $ | — |  | $ | 22 |  |  | $ | 14 |  | 36 |
Pension and other postretirement benefit plans | (10) |  | (11) |  |  | (22) |  | (21) |
Change in fair value of marketable equity securities | — |  | 11 |  |  | (4) |  | 6 |
Non-marketable investment impairments | — |  | 23 |  |  | — |  | 23 |
Other, net | (10) |  | (3) |  |  | (15) |  | (4) |
Other (income) expense, net | $ | (20) |  | $ | 42 |  |  | $ | (27) |  | $ | 40 |
Non-Cash Operating and Investing Activities Right-of-use operating lease assets obtained in exchange for lease obligations for the six months ended June 30, 2024 and 2023 were $47 million and $45 million, respectively. Purchases of property, plant and equipment included in accounts payable as of June 30, 2024 and 2023 were $52 million and $57 million, respectively.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration